ClinicalTrials.gg
RecruitingNCT07473622ORBIT-1Updated Oct 30, 2026

Outcome Research in Bowel Irrigation Techniques for the Treatment of Chronic Constipation and/or Faecal Incontinence

An interventional study of Transanal irrigation in Faecal Incontinence and Chronic Constipation, sponsored by Qufora A/S. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Qufora A/S · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 30, 2026Now RecruitingFirst site in United Kingdom+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical investigation is a post-market, exploratory, randomised, parallel, open-label investigation comparing two UKCA/CE-marked transanal irrigation products for the management of faecal incontinence and/or chronic constipation of heterogenous origin. The aim of this investigation is to assess outcomes in a real-world clinical setting, by following the typical clinical routine, with randomisation and more frequent visits/phone calls as the only difference from typical clinical procedure.

During 4-week training period, participants will trained by nurse specialists on how to use the device to which they were randomised to and will be instructed to irrigate once per day. For the remainder of the investigation, participants will be advised to continue irrigation once daily (or a minimum of 3 times a week). Participants will be followed up via phone call or in-person visit up to 52 weeks.

02

Conditions studied

  • Faecal Incontinence
  • Chronic Constipation
03

In context

Lead sponsor

Qufora A/S is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Faecal incontinence (FI), chronic constipation (CC) or co-existing FI/CC, all of heterogenous origin
  • Positive Rome IV criteria for functional constipation and/or positive Rome IV criteria for faecal incontinence
  • 18 years or older
  • Ability to understand written and spoken English (due to questionnaire validity)
  • Ability to understand and provide written, prior to any investigation-specific procedures

Exclusion criteria

Exclusion Criteria:

  • Prior use of transanal irrigation
  • Neurogenic bowel dysfunction
  • Low anterior resection syndrome (this group will be excluded due to the possibility of being randomised to a balloon catheter).
  • Previous rectal and/or anal surgery (except minor rectal or anal surgery such as haemorrhoid procedures, anal fissure surgery, drainage of a perianal/rectal abscess, or other rectal or anal surgeries deemed minor by the investigator)
  • Physical disability that affects the ability to independently use the irrigation device
  • Intermittent use of opioids inducing chronic constipation
  • Patulous anus
  • Participation in research conflicting with the current investigation
  • Physical or mental conditions affecting the ability to comply with the clinical investigation plan
  • Pregnancy or plans to become pregnant during the investigation period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Qufora QNova

    Device: Transanal irrigation

  • Active comparator
    Qufora Irrisedo Klick

    Device: Transanal irrigation

Interventions

  • DeviceTransanal irrigation

    Transanal irrigation by use of irrigation devices

06

What researchers measure

Primary outcomes

  1. Bowel Irrigation Questionnaire (BIQ) 4-point ordinal scale

    Participant experience with device (0: strongly disagree, 4: strongly agree)

    Time frame: Week 4, 10, 26, and 52

Secondary outcomes

  1. Patient Diary

    Bowel irrigation frequency (times per week)

    Time frame: Week 10, 26, and 52

  2. Patient Diary

    Bowel irrigation volume (in ml)

    Time frame: Week 10, 26, and 52

  3. Cleveland Clinic Constipation Score (CCCS)

    Constipation severity (Higher scores indicate worse constipation symptoms; score range: 0-30)

    Time frame: Week 0, 4, 10, 26, and 52

  4. St Mark's Incontinence Score (SMIS

    Fecal incontinence severity (Higher scores indicate worse incontinence symptoms; score range: 0-24)

    Time frame: Week 0, 4, 10, 26, and 52

  5. The 5-level EQ-5D (EQ-5D-5L) index score

    General health-related quality of life (measure across five dimensions; higher levels indicate greater health impairment)

    Time frame: Week 0, 4, 10, 26, and 52

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Feb 2028, 16 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 16, 2026
StartActual
Oct 9, 2026was Aug 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
1 site added — first site in United Kingdom
Show site
  • University Hospital Southampton · Southampton, United Kingdom
Oct 30, 2026
Start date
Aug 1, 2026→Oct 9, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United Kingdom
    Show site
    • University Hospital Southampton · Southampton, United Kingdom
    Start date Aug 1, 2026→Oct 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07473622
Lead sponsor
Qufora A/S
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Oct 9, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Haya N.H. Pedersen
Contact
hap@qufora.com
+45 31394941

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion